1. Home
  2. BME vs SAGE Comparison

BME vs SAGE Comparison

Compare BME & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BME
  • SAGE
  • Stock Information
  • Founded
  • BME 2005
  • SAGE 2010
  • Country
  • BME United States
  • SAGE United States
  • Employees
  • BME N/A
  • SAGE N/A
  • Industry
  • BME Trusts Except Educational Religious and Charitable
  • SAGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BME Finance
  • SAGE Health Care
  • Exchange
  • BME Nasdaq
  • SAGE Nasdaq
  • Market Cap
  • BME 525.3M
  • SAGE 444.1M
  • IPO Year
  • BME N/A
  • SAGE 2014
  • Fundamental
  • Price
  • BME $40.21
  • SAGE $7.31
  • Analyst Decision
  • BME
  • SAGE Hold
  • Analyst Count
  • BME 0
  • SAGE 20
  • Target Price
  • BME N/A
  • SAGE $10.67
  • AVG Volume (30 Days)
  • BME 34.0K
  • SAGE 1.8M
  • Earning Date
  • BME 01-01-0001
  • SAGE 02-11-2025
  • Dividend Yield
  • BME 6.26%
  • SAGE N/A
  • EPS Growth
  • BME N/A
  • SAGE N/A
  • EPS
  • BME 1.44
  • SAGE N/A
  • Revenue
  • BME N/A
  • SAGE $41,243,000.00
  • Revenue This Year
  • BME N/A
  • SAGE $123.13
  • Revenue Next Year
  • BME N/A
  • SAGE $69.65
  • P/E Ratio
  • BME $28.37
  • SAGE N/A
  • Revenue Growth
  • BME N/A
  • SAGE N/A
  • 52 Week Low
  • BME $35.53
  • SAGE $4.62
  • 52 Week High
  • BME $43.20
  • SAGE $23.22
  • Technical
  • Relative Strength Index (RSI)
  • BME 50.67
  • SAGE 60.55
  • Support Level
  • BME $40.01
  • SAGE $7.00
  • Resistance Level
  • BME $40.55
  • SAGE $7.26
  • Average True Range (ATR)
  • BME 0.38
  • SAGE 0.19
  • MACD
  • BME -0.11
  • SAGE -0.06
  • Stochastic Oscillator
  • BME 17.09
  • SAGE 57.14

About BME Blackrock Health Sciences Trust

Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Share on Social Networks: